Testosterone Replacement Therapy Guidelines
Patient Selection and Diagnosis
- For hypogonadal men, the American College of Endocrinology recommends confirming hypogonadism with morning total testosterone drawn between 8-10 AM on at least 2 separate occasions showing frankly low levels, free testosterone by equilibrium dialysis, sex hormone-binding globulin level in patients with obesity, and LH and FSH levels to distinguish primary from secondary hypogonadism 2
- If secondary hypogonadism is confirmed, further workup should include serum prolactin, iron saturation, pituitary function testing, and MRI of the sella turcica to identify underlying causes 2
Formulation Selection Algorithm
- The Endocrine Society recommends transdermal testosterone gels as first-line therapy due to stable physiologic testosterone levels and patient convenience, with intramuscular injections reserved for those with cost constraints or adherence issues 1
- Specific dosing options for transdermal gels include AndroGel 1% starting at 50 mg daily, titrating to 100 mg daily, and Testim 1% starting at 50 mg daily, titrating to 100 mg daily 3
- For cost-sensitive patients or those with poor adherence, intramuscular injections of testosterone enanthate or cypionate can be used, with a dose of 100-200 mg every 2 weeks or 50 mg weekly 3
Monitoring Protocol
- The American Urological Association recommends measuring testosterone levels 2-3 months after treatment initiation or any dose change, with timing of measurements varying by formulation 5
- For intramuscular injections, measure midway between injections, targeting mid-normal value, and for transdermal preparations, measure at any time, though peak values occur 6-8 hours after patch application 4
- Once stable levels are confirmed, monitor every 6-12 months, including testosterone levels, hematocrit/hemoglobin, PSA and prostate examination, and lipid panel 5
Safety Considerations
- The FDA warns of possible increased risk of heart attack and stroke with testosterone preparations, with some evidence suggesting intramuscular injections carry greater cardiovascular risk than gels 4
- Injections carry significantly higher erythrocytosis risk than transdermal preparations, with dose-dependent erythrocytosis occurring in 2.8-17.9% of gel users depending on dose 6
- Testosterone replacement increases prostate volume to levels equivalent to eugonadal men, but does not typically worsen voiding symptoms or cause urinary retention at higher rates than placebo 6